| Market Capitalization (Millions $) |
196 |
| Shares
Outstanding (Millions) |
3 |
| Employees |
3,500 |
| Revenues (TTM) (Millions $) |
37 |
| Net Income (TTM) (Millions $) |
5 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Sol Gel Technologies Ltd is a biopharmaceutical company that focuses on developing and commercializing innovative topical dermatological drugs. It was founded in 1997 and is headquartered in Israel. The company's research and development efforts are directed towards providing solutions to unmet needs in therapeutic dermatology.
Sol Gel Technologies specializes in the utilization of a unique, proprietary technology called "Microencapsulation Sol-Gel," which enables the development of topical drugs with improved efficacy and enhanced safety profiles. The company's products are designed to provide superior delivery of active ingredients directly to the site of dermatological action, while ensuring effective permeation through the skin barrier.
The company's flagship product is TWINRIX, the world's first combined hepatitis A and B vaccine. It is currently approved in over 100 countries, with millions of doses supplied annually. In addition, Sol Gel Technologies has a robust pipeline of other drug candidates in various stages of development, such as Encapsulated Tazarotene for the treatment of acne and Seborrheic Dermatitis, and its dermal filler platform, which aims to provide long-lasting volume restoration.
Sol Gel Technologies has partnered with various pharmaceutical companies, including GSK, AstraZeneca, and Perrigo, to develop and market its products. The company's strong intellectual property portfolio includes over 110 patents and patent applications worldwide.
Overall, Sol Gel Technologies Ltd is a promising biopharmaceutical company that is at the forefront of developing innovative topical dermatological drugs. With its proprietary technology, strong product pipeline, and strategic partnerships, the company is well-positioned to continue to deliver innovative solutions for unmet needs in therapeutic dermatology.
Company Address: 7 Golda Meir St. Ness Ziona 7403650
Company Phone Number: 8-9313429 Stock Exchange / Ticker: NASDAQ SLGL
|
1.07% 
3.65 %